FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
FDA Grants Approval for Rasonque: A Novel Targeted Therapy for Advanced Pancreatic Cancer
FOR IMMEDIATE RELEASE: August 26, 2026
The United States Food and Drug Administration (FDA) has officially authorized the use of Rasonque (daraxonrasib), a first-of-its-kind RAS inhibitor designed to treat the most prevalent variety of pancreatic cancer. By accelerating this approval, the agency has provided a vital new therapeutic option to patients with advanced disease several months earlier than originally anticipated.
This expedited action underscores the FDA's dedication to eliminating unnecessary bureaucratic delays moving with urgency to ensure that innovative, life-altering treatments reach American families and patients as quickly as possible.
🧬 Mechanism of Action and Administration
Rasonque is administered as a once-daily tablet. It specifically targets various forms of the RAS protein, which serves as a primary catalyst for malignancy in pancreatic adenocarcinoma—a cancer that originates in the cells lining the pancreatic ducts.
Pathological Pathway
"Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible." — Kyle Diamantas, J.D., Acting FDA Commissioner
📊 Clinical Impact and Patient Demographics
The approval is specifically indicated for adults suffering from metastatic pancreatic adenocarcinoma who meet one of the following criteria:
- They have already undergone at least one systemic therapy.
- They are deemed unsuitable candidates for multiagent systemic therapy.
The Burden of Pancreatic Adenocarcinoma
According to data from the National Cancer Institute, the landscape of the disease is as follows:
| Metric | Statistic |
|---|---|
| Annual New US Cases | |
| Percentage of cases that are Adenocarcinoma | |
| Share of all cancer diagnoses | |
| Mortality Rate | Disproportionately high due to late detection and aggressive nature |
Trial Results
In a multicenter, open-label, randomized study involving 500 adults with previously treated metastatic disease, the efficacy of Rasonque was compared against standard chemotherapy:
🚀 Regulatory Pathway and Acceleration
The FDA utilized several specialized programs to expedite the availability of daraxonrasib:
- Breakthrough Therapy Designation
- Orphan Drug Designation
- Commissioner’s National Priority Voucher Pilot Program (designed to prioritize national public health needs)
Angelo de Claro, M.D., Director of the FDA’s Oncology Center of Excellence, noted that the drug showed "unprecedented results" in a field with high unmet needs. Consequently, the approval was granted 6.5 months ahead of the standard user fee deadline.
Additionally, in May, the FDA issued a "safe to proceed" letter, which allowed the sponsor to implement an expanded access treatment protocol, granting some patients access to the drug before full formal approval.
⚠️ Safety Profile and Side Effects
While effective, Rasonque is associated with several adverse reactions. Patients and providers should monitor for the following:
- Gastrointestinal: Diarrhea, nausea, vomiting, abdominal pain, and stomatitis (inflammation of the mouth's mucus membranes).
- Systemic: Fatigue, edema, and hemorrhage.
- Dermatological: Rash.
- Metabolic: Decreased appetite.
📞 Contact & Agency Information
Media Inquiries: 202-690-6343
Consumer Inquiries: 888-INFO-FDA
The FDA, operating under the U.S. Department of Health and Human Services, is tasked with safeguarding public health by ensuring the security, efficacy, and safety of:
- Human and veterinary pharmaceuticals.
- Vaccines and biological products.
- Medical devices.
- The national food supply, cosmetics, and dietary supplements.
- Radiation-emitting electronics and tobacco products.
Content current as of: 08/26/2026
Regulated Product: Drugs